EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial

Elizabeth Martina Bebin iD, Jurriaan M Peters iD, Brenda E Porter, Tarrant O McPherson, Sarah O'Kelley, Mustafa Sahin iD, Katherine S Taub, Rajsekar Rajaraman, Stephanie C Randle, William M McClintock, Mary Kay Koenig, Mike D Frost und 10 weitere

Annals of Neurology · 2024-01 · 95 (1) · 15-26

DOI: 10.1002/ana.26778 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 25.09.2023. Verfasst von Elizabeth Martina Bebin und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, TSC Alliance, Bcureful.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to test the hypothesis that early vigabatrin treatment in tuberous sclerosis complex (TSC) infants improves neurocognitive outcome at 24 months of age.

Methods

A phase IIb multicenter randomized double‐blind placebo‐controlled trial was conducted of vigabatrin at first epileptiform electroencephalogram (EEG) versus vigabatrin at seizure onset in infants with TSC. Primary outcome was Bayley Scales of Infant and Toddler Development, Third Edition (Bayley‐III) cognitive assessment score at 24 months. Secondary outcomes were prevalence of drug‐resistant epilepsy, additional developmental outcomes, and safety of vigabatrin.

Results

Of 84 infants enrolled, 12 were screen failures, 4 went straight to open label vigabatrin, and 12 were not randomized (normal EEG throughout). Fifty‐six were randomized to early vigabatrin (n = 29) or placebo (n = 27). Nineteen of 27 in the placebo arm transitioned to open label vigabatrin, with a median delay of 44 days after randomization. Bayley‐III cognitive composite scores at 24 months were similar for participants randomized to vigabatrin or placebo. Additionally, no significant differences were found between groups in overall epilepsy incidence and drug‐resistant epilepsy at 24 months, time to first seizure after randomization, and secondary developmental outcomes. Incidence of infantile spasms was lower and time to spasms after randomization was later in the vigabatrin group. Adverse events were similar across groups.

Interpretation

Preventative treatment with vigabatrin based on EEG epileptiform activity prior to seizure onset does not improve neurocognitive outcome at 24 months in TSC children, nor does it delay onset or lower the incidence of focal seizures and drug‐resistant epilepsy at 24 months. Preventative vigabatrin was associated with later time to onset and lower incidence of infantile spasms. ANN NEUROL 2024;95:15–26

Autor:innen und Institutionen

  • Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Neurology, Stanford University, Stanford, CA, USA.
  • Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Harvard University, Boston, MA, USA.

ORCID-Profile: Elizabeth Martina Bebin, Jurriaan M Peters, Mustafa Sahin, Darcy A Krueger

Förderung

  • NINDS NIH HHS
  • TSC Alliance
  • Bcureful
  • Pediatric Epilepsy Research Foundation
  • National Institute of Neurological Disorders and Stroke
  • Tuberous Sclerosis Alliance

Zitieren

APA

Bebin, E. M., Peters, J. M., Porter, B. E., McPherson, T. O., O'Kelley, S., Sahin, M., Taub, K. S., Rajaraman, R., Randle, S. C., McClintock, W. M., Koenig, M. K., Frost, M. D., Northrup, H. A., Werner, K., Nolan, D. A., Wong, M., Krefting, J. L., Biasini, F., Peri, K., …, & PREVeNT Study Group (2024). Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Annals of Neurology, 95(1), 15-26. https://doi.org/10.1002/ana.26778

Vancouver

Bebin EM, Peters JM, Porter BE, McPherson TO, O'Kelley S, Sahin M, et al. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Annals of Neurology. 2024;95(1):15-26. doi:10.1002/ana.26778

BibTeX
@article{Bebin2024,
  author = {Bebin, Elizabeth Martina and Peters, Jurriaan M and Porter, Brenda E and McPherson, Tarrant O and O'Kelley, Sarah and Sahin, Mustafa and Taub, Katherine S and Rajaraman, Rajsekar and Randle, Stephanie C and McClintock, William M and Koenig, Mary Kay and Frost, Mike D and Northrup, Hope A and Werner, Klaus and Nolan, Danielle A and Wong, Michael and Krefting, Jessica L and Biasini, Fred and Peri, Kalyani and Cutter, Gary and Krueger, Darcy A and PREVeNT Study Group, PREVeNT Study Group},
  title = {Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial},
  journal = {Annals of Neurology},
  year = {2024},
  volume = {95},
  number = {1},
  pages = {15--26},
  doi = {10.1002/ana.26778}
}
Kostenlos starten →